The future of blood-based biomarkers for Alzheimer's disease

Alzheimer's and Dementia

Volumn 10, Issue 1, 2014, Pages 115-131

  Henriksen, Kim ^a   O'Bryant, Sid E ^b   Hampel, Harald ^c   Trojanowski, John Q ^d,n   Montine, Thomas J ^e   Jeromin, Andreas ^f   Blennow, Kaj ^g   Lönneborg, Anders ^h   Wyss Coray, Tony ⁱ   Soares, Holly ^j   Bazenet, Chantal ^k   Sjögren, Magnus ^h   Hu, William ^l   Lovestone, Simon ^k   Karsdal, Morten A ^a   Weiner, Michael W ^m  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d Alzheimer's Disease Core Center   (Germany)

^e UNIVERSITY OF WASHINGTON   (United States)

^f NextGen Sciences   (United States)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h DiaGenic AS   (Norway)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BRISTOL MYERS SQUIBB   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Alzheimer's disease; Biomarkers; Blood; Plasma; Serum

Indexed keywords

AMYLOID BETA PROTEIN; AUTOANTIBODY; BIOLOGICAL MARKER; MICRORNA; TAU PROTEIN; TRANSCRIPTOME;

ALZHEIMER DISEASE; ANALYTIC METHOD; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; BLOOD SAMPLING; ENDOPHENOTYPE; EVALUATION STUDY; GENETIC HETEROGENEITY; HUMAN; LIPIDOMICS; PLASMA; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; REVIEW; STANDARDIZATION;

ALZHEIMER'S DISEASE; BIOMARKERS; BLOOD; PLASMA; SERUM;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS;

EID: 84891112523     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.01.013     Document Type: Review

References (140)

1. N. Herrmann, S.A. Chau, I. Kircanski, and K.L. Lanctot Current and emerging drug treatment options for Alzheimer's disease: a systematic review Drugs 71 2011 2031 2065
2. M. Thambisetty, and S. Lovestone Blood-based biomarkers of Alzheimer's disease: challenging but feasible Biomark Med 4 2010 65 79
3. K. Blennow Biomarkers in Alzheimer's disease drug development Nat Med 16 2010 1218 1222
4. J.L. Cummings Biomarkers in Alzheimer's disease drug development Alzheimers Dement 7 2011 e13 e44
5. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, and J. Hardy et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
6. R. Mayeux, and N. Schupf Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants Neurobiol Aging 32 2011 S10 S19
7. S. Patel, R.J. Shah, P. Coleman, and M. Sabbagh Potential peripheral biomarkers for the diagnosis of Alzheimer's disease Int J Alzheimers Dis 2011 2011 572495
8. H. Zetterberg Biomarkers reflecting different facets of Alzheimer's disease Eur J Neurol 15 2008 1143 1144
9. Y. Wang, M.G. Sorensen, Q. Zheng, C. Zhang, M.A. Karsdal, and K. Henriksen Will post-translational modifications of brain proteins provide novel serological markers for dementias? Int J Alzheimers Dis 2012 2012 209409
10. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
11. J.H. Tanne US scientists discuss early detection and treatment of Alzheimer's disease BMJ 344 2012 e1068
12. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
13. H. Hampel, K. Burger, S.J. Teipel, A.L. Bokde, H. Zetterberg, and K. Blennow Core candidate neurochemical and imaging biomarkers of Alzheimer's disease Alzheimers Dement 4 2007 38 48
14. N. Mattsson, K. Blennow, and H. Zetterberg CSF biomarkers: pinpointing Alzheimer pathogenesis Ann NY Acad Sci 1180 2009 28 35
15. S.M. de Almeida, S.D. Shumaker, S.K. LeBlanc, P. Delaney, J. Marquie-Beck, and S. Ueland et al. Incidence of post-dural puncture headache in research volunteers Headache 51 2011 1503 1510
16. P. Schneider, H. Hampel, and K. Buerger Biological marker candidates of Alzheimer's disease in blood, plasma, and serum CNS Neurosci Ther 15 2009 358 374
17. J. Li, D.A. Llano, T. Ellis, D. LeBlond, A. Bhathena, and S.S. Jhee et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels Alzheimers Dement 8 2012 295 303
18. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, and A.M. Goate et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch Neurol 66 2009 1469 1475
19. A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, and A. Wall et al. PET imaging of amyloid deposition in patients with mild cognitive impairment Neurobiol Aging 29 2008 1456 1465
20. W.E. Klunk, and C.A. Mathis The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation Curr Opin Neurol 21 2008 683 687
21. C.M. Clark, M.J. Pontecorvo, T.G. Beach, B.J. Bedell, R.E. Coleman, and P.M. Doraiswamy et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study Lancet Neurol 11 2012 669 678
22. H. Hampel, S. Lista, and Z.S. Khachaturian Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot Alzheimers Dement 8 2012 312 336
23. C.B. Jeter, G.W. Hergenroeder, M.J. Hylin, J.B. Redell, A.N. Moore, and P.K. Dash Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion J Neurotrauma 30 8 2013 657 670
24. L. Papa, M.M. Ramia, J.M. Kelly, S.S. Burks, A. Pawlowicz, and R.P. Berger Systematic Review of Clinical Research on Biomarkers for Pediatric Traumatic Brain Injury J. Neurotrauma 30 5 2013 324 338
25. U. Ziemann, M. Wahl, E. Hattingen, and H. Tumani Development of biomarkers for multiple sclerosis as a neurodegenerative disorder Prog Neurobiol 95 2011 670 685
26. K.A. Josephs, R.C. Petersen, D.S. Knopman, B.F. Boeve, J.L. Whitwell, and J.R. Duffy et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP Neurology 66 2006 41 48 (Pubitemid 43739589)
27. L. Yang, D. Rieves, and C. Ganley Brain amyloid imaging-FDA approval of florbetapir F18 injection N Engl J Med 367 2012 885 887
28. World Alzheimer report 2009 2010 Published by Alzheimer's Disease International Edited by: Martin Prince & Jim Jackson
29. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, and S.E. Arnold et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
30. H.D. Soares, W.Z. Potter, E. Pickering, M. Kuhn, F.W. Immermann, and D.M. Shera et al. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease Arch Neurol 69 10 2012 1310 1317
31. A. Koyama, J. O'Brien, J. Weuve, D. Blacker, A.L. Metti, and K. Yaffe The Role of Peripheral Inflammatory Markers in Dementia and Alzheimer's Disease: A Meta-Analysis J Gerontol A Biol Sci Med Sci 68 4 2013 433 440
32. K. Blennow, M.J. de Leon, and H. Zetterberg Alzheimer's disease Lancet 368 2006 387 403 (Pubitemid 44108123)
33. D.E. Barnes, and K. Yaffe The projected effect of risk factor reduction on Alzheimer's disease prevalence Lancet Neurol 10 2011 819 828
34. G.M. McKhann, M.S. Albert, M. Grossman, B. Miller, D. Dickson, and J.Q. Trojanowski Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease Arch Neurol 58 2001 1803 1809 (Pubitemid 33044246)
35. G.D. Rosa, G. Salzano, M. Caraglia, and A. Abbruzzese Nanotechnologies: a strategy to overcome blood-brain barrier Curr Drug Metab 13 1 2012 61 69
36. S. Chalbot, H. Zetterberg, K. Blennow, T. Fladby, N. Andreasen, and I. Grundke-Iqbal et al. Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease J Alzheimers Dis 25 2011 505 515
37. Z. Cai, B. Zhao, and A. Ratka Oxidative stress and beta-amyloid protein in Alzheimer's disease Neuromolecular Med 13 2011 223 250
38. B.D. Zipser, C.E. Johanson, L. Gonzalez, T.M. Berzin, R. Tavares, and C.M. Hulette et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease Neurobiol Aging 28 2007 977 986 (Pubitemid 46635913)
39. A. Marcello, O. Wirths, T. Schneider-Axmann, M. German-Gunnarsson, L. Lannfelt, and T.A. Bayer Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease J Neural Transm 116 2009 913 920
40. S.E. O'Bryant, S.C. Waring, V. Hobson, J.R. Hall, C.B. Moore, and T. Bottiglieri et al. Decreased C-reactive protein levels in Alzheimer disease J Geriatr Psychiatry Neurol 23 2010 49 53
41. R. Ghidoni, A. Paterlini, and L. Benussi Translational proteomics in Alzheimer's disease and related disorders Clin Biochem 46 6 2013 480 486
42. M.A. Karsdal, I. Byrjalsen, A.C. Bay-Jensen, K. Henriksen, B.J. Riis, and C. Christiansen Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis - the effect of sex, Kellgren-Lawrence (KL) score, Body Mass Index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation BMC Musculoskelet Disord 11 2010 125
43. M.A. Karsdal, K. Henriksen, D.J. Leeming, T. Woodworth, E. Vassiliadis, and A.C. Bay-Jensen Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers-are they the cause or the consequence of the disease? Clin Biochem 43 2010 793 804
44. M.A. Karsdal, T. Woodworth, K. Henriksen, W.P. Maksymowych, H. Genant, and P. Vergnaud et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities Arthritis Res Ther 13 2011 215
45. M. Thambisetty, A. Simmons, L. Velayudhan, A. Hye, J. Campbell, and Y. Zhang et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease Arch Gen Psychiatry 67 2010 739 748
46. A. Hye, S. Lynham, M. Thambisetty, M. Causevic, J. Campbell, and H.L. Byers et al. Proteome-based plasma biomarkers for Alzheimer's disease Brain 129 2006 3042 3050 (Pubitemid 44684524)
47. S.J. Kiddle, M. Thambisetty, A. Simmons, J. Riddoch-Contreras, A. Hye, and E. Westman et al. Plasma based markers of [11C] PiB-PET brain amyloid burden PLoS One 7 2012 e44260
48. M. Thambisetty, A. Simmons, A. Hye, J. Campbell, E. Westman, and Y. Zhang et al. Plasma biomarkers of brain atrophy in Alzheimer's disease PLoS One 6 2011 e28527
49. M. Thambisetty, R. Tripaldi, J. Riddoch-Contreras, A. Hye, Y. An, and J. Campbell et al. Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals J Alzheimers Dis 22 2010 1099 1109
50. C. Cruchaga, J.S. Kauwe, K. Mayo, N. Spiegel, S. Bertelsen, and P. Nowotny et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease PLoS Genet 6 2012
51. D.C. Bauer, D.J. Hunter, S.B. Abramson, M. Attur, M. Corr, and D. Felson et al. Classification of osteoarthritis biomarkers: a proposed approach Osteoarthritis Cartilage 14 2006 723 727 (Pubitemid 43986366)
52. M.A. Karsdal, K. Henriksen, D.J. Leeming, P. Mitchell, K. Duffin, and N. Barascuk et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development Biomarkers 14 2009 181 202
53. S. Lista, F. Faltraco, and H. Hampel Biological and methodical challenges of blood-based proteomics in the field of neurological research Prog Neurobiol 101-102 2013 18 34
54. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362 (Pubitemid 350073592)
55. M. Britschgi, K. Rufibach, S.L. Huang, C.M. Clark, J.A. Kaye, and G. Li et al. Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome Mol Cell Proteomics 10 2011 M111
56. H.D. Soares, Y. Chen, M. Sabbagh, A. Roher, E. Schrijvers, and M. Breteler Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels Ann NY Acad Sci 1180 2009 56 67
57. M. Bjorkqvist, M. Ohlsson, L. Minthon, and O. Hansson Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease PLoS One 7 2012 e29868
58. J.D. Doecke, S.M. Laws, N.G. Faux, W. Wilson, S.C. Burnham, and C.P. Lam et al. Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease Arch Neurol 69 10 2012 1318 1325
59. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, and M. Edwards et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI PLoS One 6 2011 e28092
60. D.A. Llano, V. Devanarayan, and A.J. Simon Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Alzheimer Dis Assoc Disord 2012 [Epub ahead of print]
61. A.M. Chang, A.S. Maisel, and J.E. Hollander Diagnosis of heart failure Heart Fail Clin 5 2009 25 35
62. C. Sambanis, K. Tziomalos, E. Kountana, N. Kakavas, I. Zografou, and A. Balaska et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes Acta Diabetol 45 2008 23 30 (Pubitemid 351238273)
63. K. Buerger, A. Ernst, M. Ewers, O. Uspenskaya, M. Omerovic, and N.G. Morgenthaler et al. Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio Biol Psychiatry 65 2009 979 984
64. K. Buerger, O. Uspenskaya, O. Hartmann, O. Hansson, L. Minthon, and K. Blennow et al. Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment J Clin Psychiatry 72 2011 556 563
65. G. Wu, S. Sankaranarayanan, J. Wong, K. Tugusheva, M.S. Michener, and X. Shi et al. Characterization of plasma beta-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease J Neurosci Res 90 2012 2247 2258
66. P.G. Di, and T.W. Kim Linking lipids to Alzheimer's disease: cholesterol and beyond Nat Rev Neurosci 12 2011 284 296
67. P.L. Wood Lipidomics of Alzheimer's disease: current status Alzheimers Res Ther 4 2012 5
68. X. Han, S. Rozen, S.H. Boyle, C. Hellegers, H. Cheng, and J.R. Burke et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics PLoS One 6 2011 e21643
69. M.M. Mielke, N.J. Haughey, V.V. Bandaru, D.D. Weinberg, E. Darby, and N. Zaidi et al. Plasma Sphingomyelins are Associated with Cognitive Progression in Alzheimer's Disease J Alzheimers Dis 27 2 2011 259 269
70. B.B. Booij, T. Lindahl, P. Wetterberg, N.V. Skaane, S. Saebo, and G. Feten et al. A gene expression pattern in blood for the early detection of Alzheimer's disease J Alzheimers Dis 23 2011 109 119
71. P.D. Rye, B.B. Booij, G. Grave, T. Lindahl, L. Kristiansen, and H.M. Andersen et al. A novel blood test for the early detection of Alzheimer's disease J Alzheimers Dis 23 2011 121 129
72. P. Fehlbaum-Beurdeley, O. Sol, L. Desire, J. Touchon, T. Dantoine, and M. Vercelletto et al. Validation of AclarusDx, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer's Disease J Alzheimers Dis 32 2012 169 181
73. K. Lunnon, M. Sattlecker, S.J. Furney, G. Coppola, A. Simmons, and P. Proitsi et al. A Blood Gene Expression Marker of Early Alzheimer's Disease J Alzheimers Dis 33 3 2013 737 753
74. K. Lunnon, Z. Ibrahim, P. Proitsi, A. Lourdusamy, S. Newhouse, and M. Sattlecker et al. Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood J Alzheimers Dis 30 2012 685 710
75. S.C. Wang, B. Oelze, and A. Schumacher Age-specific epigenetic drift in late-onset Alzheimer's disease PLoS One 3 2008 e2698
76. R. Kaddurah-Daouk, S. Rozen, W. Matson, X. Han, C.M. Hulette, and J.R. Burke et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease Alzheimers Dement 7 2011 309 317
77. J.N. Lukens, D.V. Van, C.M. Clark, S.X. Xie, and F.B. Johnson Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer's disease Alzheimers Dement 5 2009 463 469
78. T. Hochstrasser, J. Marksteiner, and C. Humpel Telomere length is age-dependent and reduced in monocytes of Alzheimer patients Exp Gerontol 47 2012 160 163
79. Y. Takata, M. Kikukawa, H. Hanyu, S. Koyama, S. Shimizu, and T. Umahara et al. Association between ApoE phenotypes and telomere erosion in Alzheimer's disease J Gerontol A Biol Sci Med Sci 67 2012 330 335
80. D.M. Holtzman, A. Goate, J. Kelly, and R. Sperling Mapping the road forward in Alzheimer's disease Sci Transl Med 3 2011 114ps48
81. T. Colasanti, C. Barbati, G. Rosano, W. Malorni, and E. Ortona Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression Autoimmun Rev 9 2010 807 811
82. K.A. Gustaw-Rothenberg, S.L. Siedlak, D.J. Bonda, A. Lerner, M. Tabaton, and G. Perry et al. Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study Exp Gerontol 45 2010 47 52
83. M. Maftei, F. Thurm, V.M. Leirer, C.A. von Arnim, and T. Elbert et al. Antigen-Bound and Free beta-Amyloid Autoantibodies in Serum of Healthy Adults PLoS One 7 2012 e44516
84. E. Nagele, M. Han, C. Demarshall, B. Belinka, and R. Nagele Diagnosis of Alzheimer's disease based on disease-specific autoantibody profiles in human sera PLoS One 6 2011 e23112
85. H. Geekiyanage, G.A. Jicha, P.T. Nelson, and C. Chan Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease Exp Neurol 235 2012 491 496
86. K.S. Sheinerman, V.G. Tsivinsky, F. Crawford, M.J. Mullan, L. Abdullah, and S.R. Umansky Plasma microRNA biomarkers for detection of mild cognitive impairment Aging (Albany, NY) 4 2012 590 605
87. J.B. Toledo, H. Vanderstichele, M. Figurski, P.S. Aisen, R.C. Petersen, and M.W. Weiner et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI Acta Neuropathol 122 2011 401 413
88. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen, and H.M. Wisniewski Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol 57 2000 100 105 (Pubitemid 30027637)
89. A. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, and F. Grodstein Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis Arch Neurol 69 2012 824 831
90. H. Hampel, Y. Shen, D.M. Walsh, P. Aisen, L.M. Shaw, and H. Zetterberg et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol 223 2012 334 346
91. R.A. Rissman, J.Q. Trojanowski, L.M. Shaw, and P.S. Aisen Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease J Neural Transm 119 2012 843 850
92. F. Song, A. Poljak, M. Valenzuela, R. Mayeux, G.A. Smythe, and P.S. Sachdev Meta-analysis of plasma amyloid-beta levels in Alzheimer's disease J Alzheimers Dis 26 2011 365 375
93. A.D. Watt, K.A. Perez, A.R. Rembach, C.L. Masters, V.L. Villemagne, and K.J. Barnham Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing J Alzheimers Dis 30 2012 323 336
94. K.A. Bruggink, M. Muller, H.B. Kuiperij, and M.M. Verbeek Methods for analysis of amyloid-beta aggregates J Alzheimers Dis 28 2012 735 758
95. W. Xia, T. Yang, G. Shankar, I.M. Smith, Y. Shen, and D.M. Walsh et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease Arch Neurol 66 2009 190 199
96. M. Noguchi-Shinohara, T. Hamaguchi, I. Nozaki, K. Sakai, and M. Yamada Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease J Neurol 258 2011 1464 1468
97. J. Bielewicz, J. Kurzepa, E. Czekajska-Chehab, Z. Stelmasiak, and H. Bartosik-Psujek Does serum Tau protein predict the outcome of patients with ischemic stroke? J Mol Neurosci 43 2011 241 245
98. P.C. Liliang, C.L. Liang, H.C. Weng, K. Lu, K.W. Wang, and H.J. Chen et al. Tau proteins in serum predict outcome after severe traumatic brain injury J Surg Res 160 2010 302 307
99. J. Randall, E. Mortberg, G.K. Provuncher, D.R. Fournier, D.C. Duffy, and S. Rubertsson et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study Resuscitation 84 3 2013 351 356
100. S. Neselius, H. Zetterberg, K. Blennow, J. Randall, D. Wilson, J. Marcusson, and H. Brisby Brain Injury 2012 In Press
101. E. Portelius, R.A. Dean, M.K. Gustavsson, U. Andreasson, H. Zetterberg, and E. Siemers et al. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Res Ther 2 2 2010 7
102. N. Mattsson, L. Rajendran, H. Zetterberg, M. Gustavsson, U. Andreasson, and M. Olsson et al. BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system PLoS One 7 2012 e31084
103. J. Reifert, D. Hartung-Cranston, and S.C. Feinstein Amyloid {beta}-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation J Biol Chem 286 2011 20797 20811
104. C.A. de, L.M. Fox, R. Pitstick, G.A. Carlson, B.J. Bacskai, and T.L. Spires-Jones et al. Caspase activation precedes and leads to tangles Nature 464 2012 1201 1204
105. T.C. Gamblin, F. Chen, A. Zambrano, A. Abraha, S. Lagalwar, and A.L. Guillozet et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease Proc Natl Acad Sci USA 100 2003 10032 10037 (Pubitemid 37087063)
106. T.T. Rohn Caspase-cleaved TAR DNA-binding protein-43 is a major pathological finding in Alzheimer's disease Brain Res 1228 2008 189 198
107. Y.J. Zhang, Y.F. Xu, C.A. Dickey, E. Buratti, F. Baralle, and R. Bailey et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43 J Neurosci 27 2007 10530 10534 (Pubitemid 47501990)
108. M.R. Cookson alpha-Synuclein and neuronal cell death Mol Neurodegener 4 2009 9
109. B. De Strooper Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process Physiol Rev 90 2010 465 494
110. S. Brunholz, S. Sisodia, A. Lorenzo, C. Deyts, S. Kins, and G. Morfini Axonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells Exp Brain Res 217 3-4 2012 353 364
111. M.O. Grimm, T.L. Rothhaar, and T. Hartmann The role of APP proteolytic processing in lipid metabolism Exp Brain Res 217 3-4 2012 365 375
112. J. Avila Alzheimer disease: caspases first Nat Rev Neurol 6 2010 587 588
113. R.A. Rissman, W.W. Poon, M. Blurton-Jones, S. Oddo, R. Torp, and M.P. Vitek et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology J Clin Invest 114 2004 121 130 (Pubitemid 39071651)
114. J.Y. Sung, S.M. Park, C.H. Lee, J.W. Um, H.J. Lee, and J. Kim et al. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases J Biol Chem 280 2005 25216 25224 (Pubitemid 40934615)
115. M. Eller, and D.R. Williams alpha-Synuclein in Parkinson disease and other neurodegenerative disorders Clin Chem Lab Med 49 2011 403 408
116. B.M. Dufty, L.R. Warner, S.T. Hou, S.X. Jiang, T. Gomez-Isla, and K.M. Leenhouts et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation Am J Pathol 170 2007 1725 1738 (Pubitemid 47339316)
117. C. Yang, W. Tan, C. Whittle, L. Qiu, L. Cao, and S. Akbarian et al. The C-terminal TDP-43 fragments have a high aggregation propensity and harm neurons by a dominant-negative mechanism PLoS One 5 2012 e15878
118. I.R. Mackenzie, R. Rademakers, and M. Neumann TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia Lancet Neurol 9 2010 995 1007
119. Y.S. Chen, S.C. Lim, M.H. Chen, R.A. Quinlan, and M.D. Perng Alexander disease causing mutations in the C-terminal domain of GFAP are deleterious both to assembly and network formation with the potential to both activate caspase 3 and decrease cell viability Exp Cell Res 317 2011 2252 2266
120. K. Henriksen, Y. Wang, M.G. Sørensen, N. Barascuk, J. Suhy, and J.T. Pedersen et al. An enzyme-generated fragment of Tau measured in serum shows an inverse correlation to cognitive function PLOS One 2013 In press
121. M.L. Andersson, I.F. Petersson, K.E. Karlsson, E.N. Jonsson, B. Mansson, and D. Heinegard et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis Ann Rheum Dis 65 2006 1490 1494 (Pubitemid 44629128)
122. M.A. Karsdal, I. Byrjalsen, B.J. Riis, and C. Christiansen Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin BMC Clin Pharmacol 8 2008 12
123. S.Y. Kong, T.V. Stabler, L.G. Criscione, A.L. Elliott, J.M. Jordan, and V.B. Kraus Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis Arthritis Rheum 54 2006 2496 2504 (Pubitemid 44205010)
124. D.J. Quintana, P. Garnero, J.L. Huebner, T.N. Charni-Ben, and V.B. Kraus PIIANP and HELIXII diurnal variation Osteoarthritis Cartilage 16 2008 1192 1195
125. A. Schlemmer, C. Hassager, S.B. Jensen, and C. Christiansen Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women J Clin Endocrinol Metab 74 1992 476 480
126. L.G. Criscione, A.L. Elliott, T. Stabler, J.M. Jordan, C.F. Pieper, and V.B. Kraus Variation of serum hyaluronan with activity in individuals with knee osteoarthritis Osteoarthritis Cartilage 13 2005 837 840 (Pubitemid 41263942)
127. M.A. Karsdal, I. Byrjalsen, M. Azria, M. Arnold, L. Choi, and B.J. Riis et al. Influence of food intake on the bioavailability and efficacy of oral calcitonin Br J Clin Pharmacol 67 2009 413 420
128. U.S. Food and Drug Administration Guidance for industry: bioanalytical method validation 2001 U.S. Food and Drug Administration Rockville, MD
129. C. Belabani, S. Rajasekharan, V. Poupon, T. Johnson, and A. Bar-Or A condensed performance-validation strategy for multiplex detection kits used in studies of human clinical samples J Immunol Methods 387 1-2 2013 1 10
130. C.M. Micheel, S.J. Nass, and G.J. Omenn Evolution of translational omics: lessons learned and the path forward 2012 National Academies Press Washington, DC
131. T.J. Lyons, and A. Basu Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers Transl Res 159 2012 303 312
132. M. Madjid, and J.T. Willerson Inflammatory markers in coronary heart disease Br Med Bull 100 2011 23 38
133. F. Irie, A.L. Fitzpatrick, O.L. Lopez, L.H. Kuller, R. Peila, and A.B. Newman et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study Arch Neurol 65 2008 89 93
134. T.J. Cohen, V.M. Lee, and J.Q. Trojanowski TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies Trends Mol Med 17 2011 659 667
135. D. Ito, and N. Suzuki Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS Neurology 77 2011 1636 1643
136. V.B. Gupta, S.M. Laws, V.L. Villemagne, D. Ames, A.I. Bush, and K.A. Ellis et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging Neurology 76 2011 1091 1098
137. T. Sunderland, N. Mirza, K.T. Putnam, G. Linker, D. Bhupali, and R. Durham et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele Biol Psychiatry 56 2004 670 676 (Pubitemid 39446849)
138. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
139. C. Cruchaga, J.S. Kauwe, P. Nowotny, K. Bales, E.H. Pickering, and K. Mayo et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease Hum Mol Genet 21 2012 4558 4571
140. J.B. Toledo, J. Brettschneider, M. Grossman, S.E. Arnold, W.T. Hu, and S.X. Xie et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases Acta Neuropathol 124 2012 23 35